Physiopathogenesis of Hematological Cancer

Indexed in: Scopus, EBSCO.

The number of new discoveries related to diagnostics and therapeutics of hematological cancer is significant. These have resulted in continuous progress in fundamental knowledge about molecular and ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Molecular Targeted Therapies for Hematologic Malignancies

Pp. 218-227 (10)

Alexandre Nonino


Protein kinase inhibition has become a promising strategy for cancer therapy since the successful results obtained with Imatinib in the treatment of Chronic Myeloid Leukemia. Several other compounds that target specific kinases are now in clinical development for myeloid and lymphoid neoplasms. In this chapter we discuss the role of kinase dysregulation in hematologic malignancies and the development of inhibitors for these targets.


Protein Kinase Inhibition Abl, PDGFR Inhibitors, Philadelphia chromosome, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloproliferative Disorders, Imatinib, Second Generation Abl Inhibitors, FLT3 Inhibitors, c-KIT Inhibitors, JAK2 inhibitors, Protein Kinase C Inhibitors, Cyclin-dependent Kinase Inhibitors, mTOR inhibitors, Anaplastic Lymphoma Kinase Inhibitors, Limitations of Molecular Targeted Therapies.


Hematology Department - Hospital de Base do Distrito Federal - Brasilia, Brazil.